A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT ID: NCT05077904
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
350 participants
INTERVENTIONAL
2021-12-07
2026-04-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Staccato alprazolam Arm
Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation.
Staccato alprazolam
Route of administration: Inhalation
Participants will receive one dose of Staccato alprazolam during the Treatment Period.
Placebo Arm
Participants randomized to this arm will receive a single dose of placebo by inhalation.
Placebo
Route of administration: Inhalation
Participants will receive one dose of placebo during the Treatment Period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Staccato alprazolam
Route of administration: Inhalation
Participants will receive one dose of Staccato alprazolam during the Treatment Period.
Placebo
Route of administration: Inhalation
Participants will receive one dose of placebo during the Treatment Period.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant must have a study caregiver ≥18 years of age at the Screening Visit; the study caregiver(s) must be a relative, partner, friend, or legally authorized representative (LAR) of the participant, or a person who provides daily care to the participant and has a significant personal relationship with the participant; the study caregiver(s) must be able to recognize and observe the participant's seizures
* Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures that includes at least 1 of the following:
1. Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum total duration of 5 minutes
2. Episodes of a focal seizure with a minimum duration of 3 minutes
3. Episodes of a focal seizure or a flurry of myoclonic seizures for at least 90 seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum total duration of 3 minutes
* Prior to the Screening Visit, participant has experienced ≥4 stereotypical episodes of prolonged seizures in the past 6 months, and the last 2 stereotypical episodes of prolonged seizures must have occurred within the 3 months prior to the Screening Visit
* Participant has had a documented brain computerized tomography or magnetic resonance imaging review, performed after diagnosis of epilepsy and within the 5 years prior to the Screening Visit, that confirms the absence of a progressive neurological disorder
* Participant is receiving a regimen of antiseizure medications (ASMs) that has been stable (ie, no addition or removal of ASM\[s\]; dose adjustments are permitted to ASM\[s\]; dose adjustments are not permitted for benzodiazepines) for 30 days prior to the Screening Visit
* Male and female participants:
1. A male participant must agree to use contraception during the Outpatient Treatment Period and for at least 7 days after IMP administration and refrain from donating sperm during this period
2. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the Outpatient Treatment Period and for at least 30 days after IMP administration
* Participant is capable of giving signed informed consent (or giving assent, where required), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF), the protocol, and the individualized participant management plan (iPMP). The ICF or a specific assent form, where required, will be signed and dated by minors
* The participant's study caregiver(s) must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF, the protocol, and the iPMP
Exclusion Criteria
* Participant has a known hypersensitivity to any components of the IMP or comparable drugs (and/or an investigational device) as stated in this protocol or to albuterol (or similar bronchospasm rescue medication if needed to meet country-specific requirements)
* Participant has a diagnosis of atrial fibrillation or mitral stenosis
* Participant has a history of convulsive (generalized tonic-clonic) status epilepticus in the 8 weeks prior to the Screening Visit
* Participant has a history or presence of known nonepileptic seizures which cannot be distinguished from qualifying epileptic seizures
* Participant has a clinically significant known airway hypersensitivity (eg, bronchospasm to known allergens, such as pollen, animals, or food) and/or acute respiratory signs/symptoms (eg, shortness of breath, wheezing on lung auscultation)
* Participant has a clinically significant chronic pulmonary disorder other than mild asthma (eg, chronic obstructive pulmonary disease, restrictive lung diseases \[including idiopathic pulmonary fibrosis\]) and/or recent history or presence of hemoptysis or pneumothorax
* Participant has had a positive antigen test for acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experienced moderate to severe signs/symptoms of respiratory distress necessitating hospitalization or outpatient treatment such as ambulatory oxygen, extensive treatment with inhaler medications, and/or oral medications for a duration of 4 weeks or more, unless full resolution occurred at least 6 months prior to Screening
* Participant has experienced a upper respiratory tract infection within 4 weeks or bronchitis/pneumonia within 3 months before the Screening Visit
* Participant has a history or presence of acute narrow-angle glaucoma
* Participant has a condition for which oral alprazolam is contraindicated (eg, myasthenia gravis, severe respiratory insufficiency, and sleep apnea syndrome)
* Participant has a history or presence of long QT syndrome, a family history of sudden death due to long QT syndrome, or unexplained syncope
* Chronic use of benzodiazepines for more than 3 days within a period of 7 days will be allowed for approximately 30 % of study participants
* Participant is taking any drug that is a strong CYP3A4 inhibitor, including azole antifungal agents (ketoconazole and itraconazole) and nefazodone
* Participant is taking any opioids (eg, fentanyl, oxycodone, morphine) or sedative hypnotics on a chronic basis
* Participant is taking nonselective beta blockers on a chronic basis
* Participant is taking pharmacotherapy for an active major psychiatric disorder where major changes in regimen are needed or anticipated during the study
* Participant has been treated with vagal nerve stimulation (VNS) for less than 6 months or VNS settings have changed within 30 days before the Screening Visit
* Participant has a clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results, according to the judgment of the Investigator
* Participant has an oxygen saturation \<95 % (or less than normal in regions of altitude \>2500 meters) for greater than 30 seconds during the Screening Visit. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded
* Participant has \>2.0x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \>1.0xULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome or \>2.0xULN total bilirubin for liver impairment)
* Participant has current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis
* Participant has a QT interval corrected for heart rate (QTc) \>450 msec (males), QTc interval \>470 msec (females), or QTc interval \>480 msec (participants with bundle branch block), PR interval ≥220 msec, or any other clinically significant electrocardiogram (ECG) abnormality according to the Investigator i) The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF). It is either machine-read or manually over-read
* Participant has a positive urine screen for drugs of abuse at the Screening Visit
* Participant has a blood pressure (BP) or heart rate (HR) outside the following range after 5 minutes rest: systolic BP: 90 mmHg to 150 mmHg; diastolic BP: 4 0mmHg to 95 mmHg; HR: 50 bpm to 100 bpm. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Biopharma SRL
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Cares
Role: STUDY_DIRECTOR
001 844 599 2273 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ep0162 50506
Phoenix, Arizona, United States
Ep0162 50720
Scottsdale, Arizona, United States
Ep0162 50494
Little Rock, Arkansas, United States
Ep0162 50118
Downey, California, United States
Ep0162 50416
La Jolla, California, United States
Ep0162 50702
Long Beach, California, United States
Ep0162 50505
Los Angeles, California, United States
Ep0162 50492
Orange, California, United States
Ep0162 50367
New Haven, Connecticut, United States
Ep0162 50088
Washington D.C., District of Columbia, United States
Ep0162 50721
Boca Raton, Florida, United States
Ep0162 50515
Gulf Breeze, Florida, United States
Ep0162 50508
Jacksonville, Florida, United States
Ep0162 50342
Jacksonville, Florida, United States
Ep0162 50199
Miami, Florida, United States
Ep0162 50676
Miami, Florida, United States
Ep0162 50509
Orlando, Florida, United States
Ep0162 50703
Rockledge, Florida, United States
Ep0162 50308
Tampa, Florida, United States
Ep0162 50323
Honolulu, Hawaii, United States
Ep0162 50512
Boise, Idaho, United States
Ep0162 50493
Chicago, Illinois, United States
Ep0162 50375
Springfield, Illinois, United States
Ep0162 50504
Fort Wayne, Indiana, United States
Ep0162 50561
Lexington, Kansas, United States
Ep0162 50395
New Orleans, Louisiana, United States
Ep0162 50517
New Orleans, Louisiana, United States
Ep0162 50093
Baltimore, Maryland, United States
Ep0162 50488
Bethesda, Maryland, United States
Ep0162 50615
Boston, Massachusetts, United States
Ep0162 50047
Boston, Massachusetts, United States
Ep0162 50110
Ann Arbor, Michigan, United States
Ep0162 50507
St Louis, Missouri, United States
Ep0162 50499
Las Vegas, Nevada, United States
Ep0162 50626
Neptune City, New Jersey, United States
Ep0162 50299
New Brunswick, New Jersey, United States
Ep0162 50497
Buffalo, New York, United States
Ep0162 50625
New Hyde Park, New York, United States
Ep0162 50298
New York, New York, United States
Ep0162 50490
New York, New York, United States
Ep0162 50518
New York, New York, United States
Ep0162 50034
Rochester, New York, United States
Ep0162 50514
Charlotte, North Carolina, United States
Ep0162 50487
Charlotte, North Carolina, United States
Ep0162 50371
Akron, Ohio, United States
Ep0162 50528
Cleveland, Ohio, United States
Ep0162 50724
Portland, Oregon, United States
Ep0162 50510
Portland, Oregon, United States
Ep0162 50096
Philadelphia, Pennsylvania, United States
Ep0162 50364
Philadelphia, Pennsylvania, United States
Ep0162 50089
Philadelphia, Pennsylvania, United States
Ep0162 50511
Pittsburgh, Pennsylvania, United States
Ep0162 50491
Pittsburgh, Pennsylvania, United States
Ep0162 50700
Chattanooga, Tennessee, United States
Ep0162 50513
Memphis, Tennessee, United States
Ep0162 50722
Nashville, Tennessee, United States
Ep0162 50103
Nashville, Tennessee, United States
Ep0162 50731
Austin, Texas, United States
Ep0162 50714
Houston, Texas, United States
Ep0162 50525
Houston, Texas, United States
Ep0162 50496
Round Rock, Texas, United States
Ep0162 50473
Salt Lake City, Utah, United States
Ep0162 30016
Fitzroy, , Australia
Ep0162 30030
Herston, , Australia
Ep0162 30027
Melbourne, , Australia
Ep0162 30031
South Brisbane, , Australia
Ep0162 40650
Blagoevgrad, , Bulgaria
Ep0162 40708
Pazardzhik, , Bulgaria
Ep0162 40665
Pleven, , Bulgaria
Ep0162 40709
Pleven, , Bulgaria
Ep0162 40651
Sofia, , Bulgaria
Ep0162 20128
Beijing, , China
Ep0162 20246
Beijing, , China
Ep0162 20268
Beijing, , China
Ep0162 20299
Beijing, , China
Ep0162 20261
Changchun, , China
Ep0162 20133
Chengdu, , China
Ep0162 20137
Chengdu, , China
Ep0162 20250
Chongqing, , China
Ep0162 20334
Chongqing, , China
Ep0162 20179
Fuzhou, , China
Ep0162 20124
Guangzhou, , China
Ep0162 20260
Guangzhou, , China
Ep0162 20264
Guangzhou, , China
Ep0162 20269
Guangzhou, , China
Ep0162 20300
Guangzhou, , China
Ep0162 20022
Hangzhou, , China
Ep0162 20320
Kunming, , China
Ep0162 20258
Lanzhou, , China
Ep0162 20253
Nanchang, , China
Ep0162 20267
Nanjing, , China
Ep0162 20331
Nanning, , China
Ep0162 20333
Qingdao, , China
Ep0162 20123
Shanghai, , China
Ep0162 20292
Shanghai, , China
Ep0162 20332
Shenzhen, , China
Ep0162 20289
Shijiazhuang, , China
Ep0162 20119
Suzhou, , China
Ep0162 20257
Tianjin, , China
Ep0162 20025
Wenzhou, , China
Ep0162 20252
Wuhan, , China
Ep0162 20255
Yinchuan, , China
Ep0162 20262
Zhanjiang, , China
Ep0162 20251
Zhengzhou, , China
Ep0162 40670
Brno, , Czechia
Ep0162 40672
Ostrava - Poruba, , Czechia
Ep0162 40063
Prague, , Czechia
Ep0162 40671
Prague, , Czechia
Ep0162 40714
Prague, , Czechia
Ep0162 40681
Bron, , France
Ep0162 40688
Bron, , France
Ep0162 40680
Dijon, , France
Ep0162 40130
Marseille, , France
Ep0162 40019
Paris, , France
Ep0162 40682
Paris, , France
Ep0162 40201
Rennes, , France
Ep0162 40199
Strasbourg, , France
Ep0162 40577
Aachen, , Germany
Ep0162 40683
Berlin, , Germany
Ep0162 40685
Bielefeld, , Germany
Ep0162 40023
Erlangen, , Germany
Ep0162 40645
Frankfurt am Main, , Germany
Ep0162 40689
Kehl-kork, , Germany
Ep0162 40529
Marburg, , Germany
Ep0162 40724
München, , Germany
Ep0162 40666
Balassagyarmat, , Hungary
Ep0162 40673
Budapest, , Hungary
Ep0162 40704
Budapest, , Hungary
Ep0162 40653
Debrecen, , Hungary
Ep0162 40690
Catanzaro, , Italy
Ep0162 40674
Genova, , Italy
Ep0162 40144
Milan, , Italy
Ep0162 40477
Pavia, , Italy
Ep0162 40257
Roma, , Italy
Ep0162 40675
Roma, , Italy
Ep0162 20248
Fukuoka, , Japan
Ep0162 20070
Hachioji-shi, , Japan
Ep0162 20237
Hamamatsu, , Japan
Ep0162 20249
Hiroshima, , Japan
Ep0162 20236
Hōfu, , Japan
Ep0162 20239
Itami, , Japan
Ep0162 20143
Kodaira, , Japan
Ep0162 20315
Koshi-shi, , Japan
Ep0162 20147
Kyoto, , Japan
Ep0162 20243
Nagakute, , Japan
Ep0162 20235
Nagoya, , Japan
Ep0162 20238
Niigata, , Japan
Ep0162 20302
Osaka, , Japan
Ep0162 20241
Ōmura, , Japan
Ep0162 20316
Sapporo, , Japan
Ep0162 20297
Shinjuku-ku, , Japan
Ep0162 20240
Shizuoka, , Japan
Ep0162 20242
Suita, , Japan
Ep0162 20266
Tōon, , Japan
Ep0162 20244
Yamagata, , Japan
Ep0162 40707
Bydgoszcz, , Poland
Ep0162 40677
Gdansk, , Poland
Ep0162 40219
Krakow, , Poland
Ep0162 40502
Krakow, , Poland
Ep0162 40842
Krakow, , Poland
Ep0162 40676
Lublin, , Poland
Ep0162 40091
Nowa Sól, , Poland
Ep0162 40153
Poznan, , Poland
Ep0162 40678
Świdnik, , Poland
Ep0162 40160
Barcelona, , Spain
Ep0162 40157
L'Hospitalet de Llobregat, , Spain
Ep0162 40540
Madrid, , Spain
Ep0162 40352
Pamplona, , Spain
Ep0162 40668
Seville, , Spain
Ep0162 40453
Terrassa, , Spain
Ep0162 40230
Valencia, , Spain
Ep0162 40667
Valladolid, , Spain
Ep0162 40686
Birmingham, , United Kingdom
Ep0162 40300
Cardiff, , United Kingdom
Ep0162 40735
Glasgow, , United Kingdom
Ep0162 40163
Oxford, , United Kingdom
Ep0162 40108
Salford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-002686-18
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
U1111-1303-2588
Identifier Type: OTHER
Identifier Source: secondary_id
2024-510950-29
Identifier Type: REGISTRY
Identifier Source: secondary_id
EP0162
Identifier Type: -
Identifier Source: org_study_id